Draft Genetic Testing Policies

Blue Cross and Blue Shield of Florida partners with AIM Specialty Health®, an independent company that administers genetic testing solutions for our customers.

Third Party Disclaimer

You are about to leave Blue Cross and Blue Shield of Florida's website and enter a website operated by AIM Specialty Health® (AIM). AIM is our business associate and is an independent company that provides diagnostic testing, information and services. AIM has agreed to follow Blue Cross' privacy and security policies regarding the confidentiality and protection of your personal health information.

To continue to the AIM Specialty Health website, click "Accept” below.

Genetic Testing




Effective for dates of service January 1, 2022, and after, AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis will supersede the following policies:

  • Carrier Screening related to Cystic Fibrosis and SMA
  • Noninvasive Prenatal Screening (NIPT)

How to Submit Comments on Draft Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. 

Participating providers and other providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We accept comments for 45 days from the posting date listed on the draft policy document.

Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

Participating providers can comment on draft policies online or via mail or fax:

1. Complete our medical policy feedback form

2. Or send comments by mail or fax to:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878